Cipla completes acquisition of generic businesses in US

Cipla announced that its UK arm, Cipla (EU) Limited has closed the transaction to acquire two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc.


The acquisition was made by Cipla (EU) Limited through a wholly owned special purpose vehicle which would merge into InvaGen Pharmaceuticals Inc. after the acquisition.

The combined revenue for the two companies for the year-ended 2015 is over USD 230 million.

This acquisition is the second landmark acquisition in Cipla's 80 year history - the first was Cipla Medpro, South Africa.

The acquisition will give scale to Cipla's US business - currently 8% of total revenue as well as providing a launch pad to introduce Cipla's pipeline of products in respiratory and injectables, among others, in the coming years.

Combined with the pipeline of InvaGen products, the overall portfolio will be wide-ranging and will cover chronic therapies like CVS, CNS, respiratory, oncology and diabetes among others.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email